Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial

- At one year, improvements in fatigue were sustained among those treated with mirikizumab - - Three separate analyses of real-world data highlight the burden of fatigue and rectal urgency among people living with ulcerative colitis or Crohn's disease - INDIANAPOLIS , May 22, 2021 /PRNewswire/ --